Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP
Carleen Cullinane, Kelly Waldeck, Laura Kirby, Buck E Rogers, Peter Eu, Richard W Tothill, Rodney J Hicks
Scientific Reports | NATURE PUBLISHING GROUP | Published : 2020
Peptide receptor radionuclide therapy (PRRT) is an important treatment option for patients with somatostatin receptor-2 (SSTR2)-expressing neuroendocrine tumour (NET) though tumour regression occurs in only a minority of patients. Therefore, novel PRRT regimens with improved therapeutic activity are needed. Radiation induced DNA damage repair is an attractive therapeutic target to increase PRRT efficacy and consequently, we have characterised a panel of preclinical models for their SSTR2 expression, in vivo growth properties and response to 177Lu-DOTA-octreotate (LuTate) PRRT to identify models with features suitable for evaluating novel therapeutic combinations. In vitro studies using the S..View full abstract
Related Projects (3)
This work was supported by a Victorian Cancer Agency grant, a National Health and Medical Research Council Program grant and a Neuroendocrine Research Foundation Accelerator grant to RJH. The authors thank Rachael Walker, Kerry Ardley and Susan Jackson for in vivo technical assistance and Dr. Benjamin Blyth for helpful discussions.